Patents by Inventor Stephen Coulter
Stephen Coulter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9686990Abstract: Insecticidal, acaricidal, nematicidal or molluscicidal compounds of formula (I) wherein Y is a single bond, C?O, C?S or S(O)q where q is 0, 1 or 2; and R1, R2, R3, R4, R8, R9 are R10 are as defined in the claims or salts or N-oxides thereof, processes for preparing them and compositions containing them.Type: GrantFiled: September 21, 2015Date of Patent: June 27, 2017Assignee: Syngenta Participations AGInventors: David John Hughes, Paul Anthony Worthington, Charles Adam Russell, Eric Daniel Clarke, James Edward Peace, Mark Richard Ashton, Thomas Stephen Coulter, Richard Spurring Roberts, Louis-Pierre Molleyres, Fredrik Cederbaum, Jerome Cassayre, Peter Maienfisch
-
Publication number: 20160007608Abstract: Insecticidal, acaricidal, nematicidal or molluscicidal compounds of formula (I) wherein Y is a single bond, C?O, C?S or S(O)q where q is 0, 1 or 2; and R1, R2, R3, R4, R8, R9 are R10 are as defined in the claims or salts or N-oxides thereof, processes for preparing them and compositions containing them.Type: ApplicationFiled: September 21, 2015Publication date: January 14, 2016Applicants: SYNGENTA LIMITED, SYNGENTA PARTICIPATIONS AGInventors: David John Hughes, Paul Anthony Worthington, Charles Adam Russell, Eric Daniel Clarke, James Edward Peace, Mark Richard Ashton, Thomas Stephen Coulter, Richard Spurring Roberts, Louis-Pierre Molleyres, Fredrik Cederbaum, Jerome Cassayre, Peter Maienfisch
-
Patent number: 9174987Abstract: Insecticidal, acaricidal, nematicidal or molluscicidal compounds of formula (I) wherein Y is a single bond, C?O, C?S or S(O)q where q is 0, 1 or 2; and R1, R2, R3, R4, R8, R9 are R10 are as defined in the claims or salts or N-oxides thereof, processes for preparing them and compositions containing them.Type: GrantFiled: September 16, 2011Date of Patent: November 3, 2015Assignees: Syngenta Limited, Syngenta Participations AGInventors: David John Hughes, Paul Anthony Worthington, Charles Adam Russell, Eric Daniel Clarke, James Edward Peace, Mark Richard Ashton, Thomas Stephen Coulter, Richard Spurring Roberts, Louis-Pierre Molleyres, Fredrik Cederbaum, Jerome Cassayre, Peter Maienfisch
-
Patent number: 8697713Abstract: The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: GrantFiled: July 10, 2007Date of Patent: April 15, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Stefan Jäkel, Tanja Reuter, Stephen Murfin, Thomas Stephen Coulter, Steven Taylor
-
Patent number: 8633201Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: GrantFiled: April 10, 2007Date of Patent: January 21, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Babette Aicher, Thomas Stephen Coulter, Stefan Jaekel, Arndt-René Kelter, Stephen Murfin, Tanja Reuter, Steven Taylor
-
Publication number: 20120010220Abstract: Insecticidal, acaricidal, nematicidal or molluscicidal compounds of formula (I) wherein Y is a single bond, C?O, C?S or S(O)q where q is 0, 1 or 2; and R1, R2, R3, R4, R8, R9 are R10 are as defined in the claims or salts or N-oxides thereof, processes for preparing them and compositions containing them.Type: ApplicationFiled: September 16, 2011Publication date: January 12, 2012Applicant: SYNGENTA CROP PROTECTION LLCInventors: David John Hughes, Paul Anthony Worthington, Charles Adam Russell, Eric Daniel Clarke, James Edward Peace, Mark Richard Ashton, Thomas Stephen Coulter, Richard Spurring Roberts, Louis-Pierre Molleyres, Fredrik Cederbaum, Jerome Cassayre, Peter Maienfisch
-
Patent number: 8071607Abstract: The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: GrantFiled: December 22, 2005Date of Patent: December 6, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Thomas Stephen Coulter, Steven Taylor, Stephen Murfin, Valery Thammalaksa, Babette Aicher, Stefan Jaekel, Tanja Reuter
-
Patent number: 8039486Abstract: This invention provides compounds of Formula I, including pharmaceutically acceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.Type: GrantFiled: February 8, 2008Date of Patent: October 18, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Kap-Sun Yeung, Michelle E. Farkas, John F. Kadow, Nicholas A. Meanwell, Malcolm Taylor, David Johnston, Thomas Stephen Coulter, J. J. Kim Wright
-
Publication number: 20100234377Abstract: The present invention relates to compounds of general formula (I): wherein A, Y, X, n and B are as defined herein; and their use in the treatment and prevention of metabolic disorders, inflammatory conditions, allergic conditions, fever, pain including allodynia and nociception, eating disorders, cachexia, brain injuries, cancer of the genitals, sleep apnea, cardiovascular disease, flush effect associated with nicotinic acid and related compounds or for the promotion of wound healing. Certain compounds of general formula (I) are new and the invention also relates to these compounds and to their use in medicine.Type: ApplicationFiled: April 7, 2008Publication date: September 16, 2010Applicant: Evotec AGInventors: Babette Aicher, Arndt-Rene Kelter, Thomas Stephen Coulter, Steven Taylor, Adams James Davenport, Thomas Hesterkamp, Christian Kirchhoff
-
Publication number: 20100143341Abstract: The present invention relates to novel pharmaceutical compositions of general formula (I) comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: ApplicationFiled: June 21, 2006Publication date: June 10, 2010Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Steven Taylor, Stephen Murfin, Thomas Stephen Coulter, Stefan Jakel, Babette Aicher, Arndt-Rene Kelter, Joachim Kraemer, Christian Kirchhoff, Andreas Scheel, Julian Woelcke
-
Publication number: 20100105708Abstract: The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: ApplicationFiled: July 10, 2007Publication date: April 29, 2010Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Stefan Jäkel, Tanja Reuter, Stephen Murfin, Thomas Stephen Coulter, Steven Taylor
-
Publication number: 20100056548Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: ApplicationFiled: April 10, 2007Publication date: March 4, 2010Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Babette Aicher, Thomas Stephen Coulter, Stefan Jaekel, Arndt-René Kelter, Stephen Murfin, Tanja Reuter, Steven Taylor
-
Publication number: 20090215778Abstract: Derivatives of pyrazolopyrimidine compounds represented by Formula I are disclosed: These pyrazolopyrimidine derivatives and pharmaceutical compositions comprising these derivatives are useful in the treatment of HIV mediated diseases and conditions.Type: ApplicationFiled: April 28, 2008Publication date: August 27, 2009Applicant: Panacos Pharmaceuticals, Inc.Inventors: Theodore J. Nitz, Karl Salzwedel, Catherine Finnegan, Shirley Brunton, Stuart Flanagan, Christian Montalbetti, Thomas Stephen Coulter
-
Publication number: 20090163520Abstract: The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: ApplicationFiled: December 22, 2005Publication date: June 25, 2009Inventors: Thomas Stephen Coulter, Stephen Taylor, Stephen Murfin, Valery Thammalaksa, Babette Aicher, Stefan Jaekel, Tanja Reuter
-
Publication number: 20090069323Abstract: The invention relates to compounds of formula (I) wherein A, Y, Z1, Z2, R1 to R3 and X1 to X4 have the meaning as cited in the description and the claims. For example A is 4?-fluorobiphen-4-yl; Y is —S(O)2NH—; R1, R2 are H; X1, X2, X4 are CH; X3 is C—F; Z1 is ?O; and Z2-R3 is N(CH2CH3)2. Said compounds are useful as 11?-HSD1 inhibitors. The invention also relates to the preparation of such compounds as well as the production and use as medicament.Type: ApplicationFiled: November 8, 2005Publication date: March 12, 2009Applicant: Evotec AGInventors: Thomas Stephen Coulter, Steven Taylor, Tara Fryatt, Babette Aicher, Martin Schneider
-
Publication number: 20080132516Abstract: This invention provides compounds of Formula I, including pharmaceutically acceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.Type: ApplicationFiled: February 8, 2008Publication date: June 5, 2008Inventors: Kap-Sun Yeung, Michelle E. Farkas, John F. Kadow, Nicholas A. Meanwell, Malcolm Taylor, David Johnston, Thomas Stephen Coulter, J.J Kim Wright
-
Publication number: 20060169287Abstract: A condom having a first lubricating composition containing a male genitalia desensitizing agent on the inside surface thereof and a second lubricating composition on the outside surface thereof. The first lubricating composition has a higher viscosity than the second lubricating composition so that the first lubricating composition remains on the inside surface of the condom during packaging, shipping, storage, and use.Type: ApplicationFiled: April 4, 2006Publication date: August 3, 2006Applicant: CHURCH & DWIGHT CO., INC.Inventors: Michael Harrison, Dennis Blum, Gisela McBride, Stephen Coulter, Peter Burke
-
Patent number: 7081456Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: GrantFiled: November 21, 2003Date of Patent: July 25, 2006Assignee: Active Biotech ABInventors: Ian Richard Matthews, Thomas Stephen Coulter, Chiara Ghiron, Chris James Brennan, Muhammed Kamal Uddin, Lars Olof Göran Pettersson, Dorthe da Graca Thrige, Philip Huxley
-
Publication number: 20040116461Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: ApplicationFiled: November 21, 2003Publication date: June 17, 2004Applicant: ACTIVE BIOTECH ABInventors: Ian Richard Matthews, Thomas Stephen Coulter, Chiara Ghiron, Chris James Brennan, Muhammed Kamal Uddin, Lars Olof Goran Pettersson, Dorthe da Graca Thrige, Philip Huxley